OXIS International, Inc. (OTC: OXIS)develops innovative drugs focused on the treatment of cancer and other unmet medical needs.  OXIS’ lead drug candidate, DT2219ARL, is a novel bispecific scFv recombinant fusion protein-drug that simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors.  OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. OXIS’ lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC).  For more information, visit the company’s website at www.oxis.com.